key: cord-0932439-iali360u authors: Cadegiani, Flavio A.; Goren, Andy; Wambier, Carlos G.; McCoy, John title: Early COVID-19 Therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in Outpatient Settings Significantly Improved COVID-19 outcomes compared to Known outcomes in untreated patients date: 2021-07-07 journal: New Microbes New Infect DOI: 10.1016/j.nmni.2021.100915 sha: 6af63e7070b92a0accf07225360ba51d163f6dc1 doc_id: 932439 cord_uid: iali360u In a prospective observational study (pre-AndroCoV Trial), the use of nitazoxanide, ivermectin and hydroxychloroquine demonstrated unexpected improvements in COVID-19 outcomes, when compared to untreated patients. The apparent yet likely positive results raised ethical concerns on the employment of further full placebo84 controlled studies in early stage COVID-19. The present analysis aimed to elucidate whether full placebo-control randomized clinical trials (RCTs) on early-stage COVID-19 are still ethically acceptable, through a comparative analysis with two control87 groups. Active group (AG) consisted of patients enrolled in the Pre AndroCoV-Trial (n = 585). Control Group 1 (CG1) consisted of a retrospectively obtained group of untreated patients of the same population (n = 137), and Control Group 2 (CG2) resulted from a precise prediction of clinical outcomes based on a thorough and structured review of indexed articles and official statements. Patients were matched for sex, age, comorbidities and disease severity at baseline. Compared to CG1 and CG2 AG showed reduction of 31.5-36.5% in viral shedding (p < 0.0001), 70-85% in disease duration (p < 0.0001), and 100% in respiratory complications, hospitalization, mechanical ventilations, and deaths (p < 0.0001 for all). For every 1,000 confirmed cases for COVID-19, at least 70 hospitalizations, 50 mechanical ventilations and five deaths were prevented. Benefits from the combination of early COVID-19 detection and early pharmacological approaches were consistent and overwhelming when compared to untreated groups, which, together with and well-established safety profile of the drug combinations tested in the Pre-AndroCoV Trial, precluded our study to continue employing full placebo in early COVID-19. , that is particularly harmful for those aged above 60 y/o, with uncontrolled diabetes, hypertension, obesity, androgenetic alopecia (AGA), and abuse of anabolic steroids in males (2) (3) (4) (5) and hyperandrogenism in females (6, 7) Effective treatments to improve COVID-19 clinical outcomes, mortality and to prevent post-COVID manifestations are highly desired while definitive solutions such as effective and safe vaccines are not universally available. Pharmacological interventions during the viral replication stage are likely the best timing to antagonize SARS-CoV-2 infectivity and prevent complications (1, 3) . Hydroxychloroquine (HCQ), nitazoxanide (NIT) and ivermectin (IVE), in association with azithromycin (AZI), are popular drugs largely used as off label therapies for early COVID-19. Despite the demonstration of direct or indirect antiviral activity and positive preliminary observations when treatment is started before seven days of symptoms, all of these three drugs -HCQ (8) (9) (10) (11) (12) (13) , IVE (13) (14) (15) (16) (17) (18) , and NIT (18) (19) (20) (21) (22) lack definitive data regarding their efficacy for COVID-19. Since the plausibility for their use in COVID-19 is based on their potential antiviral activity, these drugs failed to demonstrate benefits when were tested after the first stage, as expected (16, 23) , despite a few exceptions (24) . In addition to the above-mentioned drugs, antiandrogens could play a protective action against COVID-19 by the inhibition of transmembrane serine protease 2 (TMPRSS-2) expression, a critical protein that facilitates SARS-CoV-2 viral entry, that finds in androgens its only known modulators (3, 4, (25) (26) (27) (28) (29) (30) (31) (32) . Indeed, chronic dutasteride use (28) (29) (30) and acute dutasteride (31) and proxalutamide (32) Our first objective was to compare antiandrogens, HCQ, NIT, IVE, and placebo, for early COVID-19, based on the assumption that none of these drugs presented actual benefits for any COVID-19 stage (null hypothesis). We first conducted a prospective open-label head-to-head comparison observational study with HCQ, NIT and IVE, with or without antiandrogens, to detect whether any of these drugs would demonstrate superior efficacy, and then test the most effective options in double-blind placebo-controlled randomized clinical trials (RCTs), alone and combined with spironolactone (SPIRO), dutasteride (DUTA), or proxalutamide (PROXA) (33) (34) (35) . However, during the observational study, interim analysis demonstrated that while HCQ, NIT and IVE showed similar effects, outcomes were seemingly more effective than those expected for COVID-19. The unexpected, seemingly positive results compelled us to question whether the employment of full placebo-control studies in early stage COVID-19 would still remain ethically acceptable ( Figure 1 ). The objective of the present study was to elucidate whether a full placebo control RCT in early COVID-19 would still be ethically acceptable after the results obtained in the pre-AndroCoV Trial. To answer to this question, we performed independent comparisons with two distinct control-groups matched for sex, age, comorbidities, and disease characteristics: of untreated patients with COVID-19 from the same location as the subjects enrolled in the Pre-AndroCoV Trial, and of a control1 group with the expected outcomes, based on data generated from a thorough and structured review of the literature. With these comparative analyses, we aimed to evaluate whether differences in COVID-19 outcomes actually exist between treated with different regimens and untreated subjects, how different COVID-19 outcomes were, the expected implications of these differences in terms of prevention of hospitalizations, mechanical ventilations, deaths, and post-COVID symptoms, and if these discrepancies were sufficient to be considered as irrefutable, leading to mandatory changes in the design of further RCTs conducted on early COVID-19, in terms of no longer employing full placebo groups. J o u r n a l P r e -p r o o f The study was conducted in a single center (Corpometria Institute, Brasilia, Brazil). Two control-groups were employed, and both were adjusted for age, sex, and presence of comorbidities. Control Group 1 (CG1) (n=137) was a group of paired untreated patients randomly obtained retrospectively from the population of the same community that had confirmed diagnosis of COVID-19 during the same period of those included in the Pre-AndroCoV Trial, that either refused or did not receive specific treatments for COVID-19 including nitazoxanide, hydroxychloroquine or ivermectin. A second control group (Control Group 2 -CG2) (paired for 585 patients) resulted from a precise estimative based on a thorough and structured review of articles indexed in PubMed and MEDLINE and statements by official government agencies and specific medical societies (2, , in addition to the living systematic review of the British Medical Journal expected estimates for each outcome in untreated patients (11) . From data obtained, each parameter was estimated for range, median and consistency, and the least negative data was employed, aiming to underestimate the risks of non-treatment to avoid overestimation of differences between treatment regimens and lack of treatment. When results had above 20% of discrepancy between different sources, the least negative value was employed. When results had differences lower than 20% for a same parameter between studies, the value employed was one standard deviation (SD) below the median in favor of positive outcomes. When a specific parameter had differences above 100%, the range, instead of a specific value, was described (e.g., if the prevalence J o u r n a l P r e -p r o o f of 202 a specific symptom was described as being between 10% and 80%, 10%-80% was described, instead of 45%). For these parameters, the least negative value was employed for comparison purposes with AG. The parameters of the CG2 group were estimated from the proportion between rates for those aged between 40 and 49 y/o with and without comorbidities, assuming a prevalence of comorbidities of 20% (compared to 30% of comorbidities in the AG). For CG2, we avoided statistical analyses from regions with higher case fatality ratio (CFR), as those observed in Northern Italy (69) , as this could artificially increase the estimation of the number of preventable complications related to COVID-19. Selected subjects were characterized for age, sex, prevalence of obesity, hypertension, type 2 diabetes mellitus, overall comorbidities rate, and adjusted accordingly. AC were additionally characterized for the presence of other 35 diseases and 20 drug classes. The medical records of the subjects were recorded individually, medically analyzed in an individual bases, while data was compiled into a dataset and deidentified for statistical analysis purposes. The detailed description of the allocation process is described elsewhere (18) . Treatment was optional and all offered drugs were within standard of care was provided, since all early specific pharmacological approaches were based on the literature or as per the Brazilian Government (REF). Drug options were offered in a CG1 and CG2 underwent pairwise comparative analysis to evaluate consistency between world data of untreated subjects and data generated from the local untreated population. Only parameters with minimally sufficient data and consisting findings between different studies were included. Amplitude effectestimated number of preventable outcomes. Since preliminary data demonstrated that hospitalizations, deaths and post-COVID syndrome were likely prevented in the AG, we calculated estimates for the number of patients that avoided progression to any of these complications with treatment regimens. Full raw data for AC and CG1 is available at a public repository (https://osf.io/cm4f8/). Sample size was determined based on the assumptions that its estimate for the chisquared test would require 80% power to detect the difference in proportions at p = 0.05, at least 95% of subjects would complete the study, and hospitalization and death rates being between 3 and 20%, and 0.3 and 2.5%, respectively. From these assumptions, we calculated a minimum of 45 and 125 patients for each subjects to detect safety and efficacy differences, respectively, that could justify its early termination. Nonparametric ANOVA (Kruskal-Wallis) with adjusted Dunn's test for pairwise analyses when overall p < 0.05, assuming that all parameters were distributed non normally. All statistical tests were performed using XLSTAT version 22.4.1 (Microsoft, USA). Baseline characteristics are presented in Table 1 . Proportion between sex, age, and comorbidities were similar between treated population (AG) and both control-group 1 J o u r n a l P r e -p r o o f (CG1) and control-group 2 (CG2), except for obesity, that was estimated to be more prevalent in the expected population (CG2) than in AG and CG1. Hypertension and type 2 diabetes were numerically more prevalent in treated population, although not statistically significant. Main clinical outcomes are summarized in Table 2 . The percentage of asymptomatic was 6.6% in the AG group, 13.3% in the CG1 group, and estimates vary between 15% and 80% of patients expected to be asymptomatic. The expected control population has estimates statistically significantly higher proportions of asymptomatic patients than the groups that were followed-up (overall p < 0.0001). When we conducted the observational study comparing HCQ, NIT and IVE, we presumed that there were no actual effective options for early COVID-19, i.e., that none of the drugs would confer any protection. As per the design, we did not include patients that did not undergo any specific treatment, since our primary objective was to perform a head-to-head comparison. However, once none of the patients were hospitalized, needed mechanical ventilation, or deceased, questions regarding the superiority of any treatment over none were raised, but could not be answered by the study, as we did not originally include untreated patients, precluding us from any conclusion regarding the overall efficacy. To respond to this question raised by the clear differences between While differences were in subjects with median age below 60 y/o, in subjects above 60 y/o differences could be more pronounced. Since our study only had fewer than 15% of patients being asymptomatic, the expected CFR for our population was higher than for those obtained through the analysis of seroprevalence. Our prevalence of comorbidities was higher compared to sex-and age-matched untreated populations, even with lower BMI (when compared to CG2, but no CG1), possibly because we have actively searched for comorbidities that could influence risks in COVID-19. This could have negatively influenced outcomes in the AG, although underdiagnosis of comorbidities in CG2 is possible. Whether and until which extent the change in COVID-19 detection towards a more sensitive diagnosis may have affected outcomes in a positive manner is unknown, but possible. Correspondingly, a more aggressive approach to the patient suspected for COVID-19 may have been crucial for the better outcomes found in the AG, when compared CGs. While mortality plays a key outcome in COVID-19, the notorious presence of persisting symptoms after COVID-19 remission has called attention to the chronic aspects, possibly mediated by the triggering of immunologic maladaptations. Persistent fatigue, brain fog, reduction of cognitive functions, impaired muscle recovery, decreased physical capacity, reduced fertility and sexual function, and psychiatric In the present study, differences in the prevalence of post-COVID symptoms between treated and untreated populations were greater than differences observed in any other parameter. This finding must be emphasized as an additional benefit that may overcome potential risks of the drugs use per se, i.e., even in a hypothetical absence of other benefits, prevention of post-COVID syndrome may alone be sufficient to justify the use of early pharmacological approaches for COVID-19. There is not a specific point from which it becomes ethically questionable to continue a clinical trial (68, 69) . However, the fact that a placebo control is necessary to demonstrate efficacy is not sufficient to justify its employment in all circumstances. In the case of HCQ, IVE and NIT use for early COVID-19, the prevention of 7%, 5% and 50% to 80% of subjects being hospitalized, intubated, and suffering from chronic manifestations, respectively, their well-established safety profile for outpatient use and the social value of early treatment in a pandemic are arguments against the continuation of placebo-controlled studies for early COVID-19. In addition, the estimates for clinical outcomes in COVID-19 are largely based on population studies with positive rtPCR-SARS-CoV-2, not only tested due to symptoms or close contact with infected subjects. This is seen by the large percentage of asymptomatic patients expected for this group. This may underestimate the hospitalization and mortality rates in the estimates of the GC2. Once hydroxychloroquine, nitazoxanide and ivermectin have been used for a wide range of disease in the long-term for large populations with favorable cost-effectiveness even when used prophylactically, it is intuitive that their use for early COVID-19, when antiviral approaches tend to be more efficient, would be recommended, at least until evidence shows otherwise. Since the development of severe respiratory states can occur very rapidly in COVID-19, the timing to intervention is critical, and early pharmacological approaches showed to be likely efficient to prevent acute respiratory insufficiency. Because COVID-19 is of public health importance, and impact of the present findings is likely large, we were no longer ethically allowed to conduct studies with employment of full placebo, and we found mandatory to communicate our findings to overall scientific community. Figure 2 summarizes the rationale for the conclusions from the present analysis. This is a post-hoc comparative analysis that compared a group of treated patients with a variety of drug combinations with two control-groups, one obtained retrospectively and one estimated for the population treated for COVID-19 with several biases, which is only able to offer evidence due to the overwhelming differences. In particular, drugs that could disclose different results were combined altogether for comparison purposes. That included hydroxychloroquine, ivermectin, and nitazoxanide. Although our previous observational study demonstrated similar outcomes, a formal randomized clinical trial for head-to-head comparisons have not been performed. In addition, all patients received a combination of one of these three drugs and azithromycin. Whether: 1. Azithromycin would work alone; and 2. Combination between hydroxychloroquine, ivermectin, and nitazoxanide would yield better results are unknown. However, due to the complex pathophysiology, it is plausible that therapies with different targets against SARS-CoV-2 may present synergistic activity and higher efficacy. The last but important limitation is that this observational study was conducted during the occurrence of previous viral strains. The novel P.1 Variant of Concern (VOC), that surged in the country where the experiment was conducted, was shown to present higher infectivity, pathogenicity, and poorer outcomes, with characteristics that could fulfill criteria to become the first Variant of High Consequence (VOHC) (70) . In this case, multidrug combined therapies tend to be more effective than testing or administering one or two drugs only. Patients treated with azithromycin combined with nitazoxanide, hydroxychloroquine or The funding of present study 442 was fully supported by Corpometria Institute (Brasilia, DF, Brazil) and Applied Biology Inc (Irvine, CA, USA). Authors declare no conflict of interest with any of the pharmacological interventions proposed by the present study. J o u r n a l P r e -p r o o f Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis Repurposing existing drugs for COVID-19: an endocrinology perspective COVID-19, androgens, and androgenic alopecia Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients Potential risk for developing severe COVID-19 disease among anabolic steroid users Clinical symptoms of hyperandrogenic women diagnosed with COVID-19 Increased COVID-19 infections in women with polycystic ovary syndrome: a population-based study Hydroxychloroquine: A comprehensive review and its controversial role in coronavirus disease 2019 A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics Prophylaxis against covid-19: living systematic review and network meta-analysis From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2? Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? Cells Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines Epub ahead of print Interventions in an Ambulatory Setting to Prevent Progression to Severe Disease in Patients With COVID-19: A Systematic Review Inhibition of vaccinia virus replication by nitazoxanide. Virology Nitazoxanide and JIB-04 have broad-spectrum antiviral activity and inhibit SARS-CoV-2 replication in cell culture and coronavirus pathogenesis in a pig model SARITA-2 investigators. Early use of nitazoxanide in mild Covid-19 disease: randomised, placebocontrolled trial Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19? Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials Nitazoxanide superiority to placebo to treat moderate COVID-19 A Pilot prove of concept randomized double-blind clinical trial Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension? Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS) Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus J o u r n a l P r e -p r o o f (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) Front Med (Lausanne) 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men Albe rtoSaita, The Humanitas COVID-19 Task Force Rosanna As selta Impact of anti-androgen therapies on COVID-19 susceptibility: a case-control study in male population from two COVID-19 regional centers of Lombardy Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized Hydroxychloroquine, nitazoxanide and ivermectin have similar effects in early COVID-19: a head-to-head515 comparison of the Pre-AndroCoV Trial Azithromycin with nitazoxanide, hydeoxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-tomoderate COVID-19 An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study Report of the WHO-China Joint Mission on Coronavirus DIsease Estimates of the severity of coronavirus disease 2019: a model-based analysis Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy Cecconi 541 M. Critical Care Utilization for the COVID-19 Early Experience and Forecast During an Emergency Response A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates Excess Deaths From COVID-19 and Other Causes Coronavirus Disease 2019 Case Surveillance -United States Association between male sex and outcomes of Coronavirus Disease 2019 (Covid-19) -a Danish nationwide, register553 based study Hospitalization and Mortality among Black Patients and White Patients with Covid-19 Characteristics of Persons Who Died with COVID-19 -United States Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical Characteristics of Covid-19 in New York City The 566 Early Natural History of SARS-CoV-2 Infection: Clinical Observations From an Urban Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19 Natural History and Clinical Course of Symptomatic and Asymptomatic COVID-19 Patients in the Kingdom of Saudi Arabia 589 Post-COVID 19 Neurological Syndrome (PCNS); a novel syndrome with challenges for the global neurology community How NETosis could drive "Post-COVID-19 syndrome" among survivors Assessment and Characterization of Post-COVID-19 manifestations Post COVID-19 syndrome associated with orthostatic cerebral hypoperfusion syndrome, small fiber neuropathy and benefit of immunotherapy: a case report. eNeurologicalSci Covid-19 hyperinflammation and post Covid-19 illness may be rooted in mast cell activation syndrome Post COVID Syndrome (PCS) and healthcare workers: who cares for the carers? QJM Characteristics and predictors of acute and chronic post-COVID syndrome: A systematic review and meta-analysis. EClinicalMedicine Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis Health-related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19; a systematic literature review International ethical guidelines for biomedical research involving human subjects.Council for International Organizations of Medical Sciences International ethical guidelines for biomedical research involving human subjects.Council for International Organizations of Medical Sciences Characterization of a new SARS-CoV-2 variant that emerged in Brazil FIGURE LEGENDS Figure 1. Rationale for the ethical questioning on the employment of placebo-control design in RCTs for Ethics in the employment of full placebo-control RCTs in early COVID-19 Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Improved Outcomes Compared to Known Outcomes in Untreated Patients